|
1
|
Luo J, Solimini NL and Elledge SJ:
Principles of cancer therapy: oncogene and non-oncogene addiction.
Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: a radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fruehauf JP and Meyskens FL Jr: Reactive
oxygen species: a breath of life or death? Clin Cancer Res.
13:789–794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sporn MB and Liby KT: NRF2 and cancer: the
good, the bad and the importance of context. Nat Rev Cancer.
12:564–571. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wondrak GT: Redox-directed cancer
therapeutics: molecular merchanisms and opportunities. Antioxid
Redox Signal. 11:3013–3069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kansanen E, Kuosmanen SM, Leinonen H and
Levonen AL: The Keap1-Nrf2 pathway: mechanism of activation and
dysregulation in cancer. Redox Biology. 1:45–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stendel R, Picht T, Schilling A,
Heidenreich J, Loddenkemper C, Jänisch W and Brock M: Treatment of
glioblastoma with intravenous Taurolidine. First clinical
experience. Anticancer Res. 24:1143–1147. 2004.PubMed/NCBI
|
|
9
|
Braumann C, Winkler G, Rogalla P,
Menenakos C and Jacobi CA: Prevention of disease progression in a
patient with a gastric cancer-recurrence. Outcome after intravenous
treatment with the novel antineoplastic agent Taurolidine. Report
of a case. World J Surg Oncol. 4:342006. View Article : Google Scholar
|
|
10
|
McCartney AC and Browne MK: Clinical
studies on administration of taurolidine in severe sepsis: a
preliminary study. Progr Clin Biol Res. 272:361–371.
1988.PubMed/NCBI
|
|
11
|
Staubach KH: Adjuvant therapy of
peritonitis with taurolidine. Modulation of mediator liberation.
Langenbecks Arch Chir. 382:S26–S30. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Braumann C, Gutt CN, Scheele J, Menenakos
C, Willems W, Mueller JM and Jacobi CA: Taurolidine reduces the
tumor-stimulating cytokine IL 1beta in patients with resectable
gastrointestinal cancer: a multicenter prospective randomized
trial. World J Surg Oncol. 7:32–45. 2009. View Article : Google Scholar
|
|
13
|
Wesch G, Petermann C and Linder MM: Drug
therapy of peritonitis: 6-year experience with the chemotherapeutic
agent and anti-endotoxin Taurolin. Fortschr Med. 101:545–550.
1983.PubMed/NCBI
|
|
14
|
Raj L, Ide T, Gurkar AU, Foley M, Schenone
M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM,
Mandinova A, Schreiber SL and Lee SW: Selective killing of cancer
cells by a small molecule targeting the stress response to ROS.
Nature. 475:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parkinson EI and Hergenrother PJ: Runaway
ROS as selective anticancer strategy. Chem Med Chem. 6:1957–1959.
2011. View Article : Google Scholar
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
18
|
Pfirrmann RW: Taurolin, ein neues Konzept
zur antimikrobiellen Chemotherapie chirurgischer Infektionen.
Brückner WL and Pfirrmann RW: Urban and Schwarzenberg Verlag; 1985,
(In German).
|
|
19
|
Rodak R, Kubota H, Ishihara H, Eugster HP,
Könü D, Möhler H, Yonekawa Y and Frei K: Induction of reactive
oxygen intermediates- dependent programmed cell death in human
malignant ex vivo glioma cells and inhibition of the vascular
endothelial growth factor production by Taurolidine. J Neurosurg.
102:1055–1068. 2005. View Article : Google Scholar
|
|
20
|
Stendel R, Biefer HR, Dékany M, Kubota H,
Münz C, Wang S, Möhler H, Yonekawa Y and Frei K: The antibacterial
substance Taurolidine exhibits anti-neoplastic action based on a
mixed type of programmed cell death. Autophagy. 5:194–210. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Calabresi P, Goulette FA and Darnowski JW:
Taurolidine: cytotoxic and mechanistic evaluation of a novel
antineoplastic agent. Cancer Res. 61:6816–6821. 2001.PubMed/NCBI
|
|
22
|
Aceto N, Bertino P, Barbone D, Tassi G,
Manzo L, Porta C, Mutti L and Gaudio G: Taurolidine and oxidative
stress: a rationale for local treatment of mesothelioma. Eur Respir
J. 34:1399–1407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nici L, Monfils B and Calabresi P: The
effects of Taurolidine, a novel antineoplastic agent, on human
malignant mesothelioma. Clin Cancer Res. 10:7655–7661. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Opitz I, Sigrist B, Hillinger S, Lardinois
D, Stahel R, Weder W and Hopkins-Donaldson S: Taurolidine and
povidone-iodine induce different types of cell death in malignant
pleural mesothelioma. Lung Cancer. 56:327–336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Darnowski JW, Goulette FA, Cousens LP,
Chatterjee D and Calabresi P: Mechanistic and antineoplastic
evaluation of Taurolidine in the DU145 model of human prostate
cancer. Cancer Chemother Pharmacol. 54:249–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stendel R, Stoltenburg-Didinger G and
Brock M: Apoptotic changes in brain tumor cells induced by
Taurolidine. J Cancer Res Clin Oncol. 128:1502002.
|
|
27
|
Stendel R, Stoltenburg-Didinger G, Al
Keikh CL, Wattroth M and Brock M: The effect of Taurolidine on
brain tumor cells. Anticancer Res. 22:809–814. 2002.PubMed/NCBI
|
|
28
|
Ribizzi I, Darnowski JW, Goulette FA,
Akhtar MS, Chatterjee D and Calabresi P: Taurolidine: preclinical
evaluation of a novel, highly selective, agent for bone marrow
purging. Bone Marrow Transplant. 29:313–319. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McCourt M, Wang JH, Sookhai S and Redmond
HP: Taurolidine inhibits tumor cell growth in vitro and in vivo.
Ann Surg Oncol. 7:685–691. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nestler G, Schulz HU, Schubert D, Krüger
S, Lippert H and Pross M: Impact of Taurolidine on the growth of
CC531 coloncarcinoma cells in vitro and in a laparoscopic animal
model in rats. Surg Endosc. 19:280–284. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Braumann C, Schoenbeck M, Menenakos C,
Kilian M and Jacobi CA: Effects of increasing doses of a bolus
injection and an intravenous long-term therapy of Taurolidine on
subcutaneous (metastic) tumor growth in rats. Clin Exp Metastasis.
22:77–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hoksch B, Rufer B, Gazdhar A, Bilici M,
Beshay M, Gugger M and Schmid RA: Taurolidine in the prevention and
therapy of lung metastases. Eur J Cardiothorac Surg. 36:1058–1063.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chromik AM, Daigeler A, Hilgert C, Bulut
D, Geisler A, Liu V, Otte JM, Uhl W and Mittelkötter U: Synergistic
effects in apoptosis induction by Taurolidine and TRAIL in HCT-15
colon carcinoma cells. J Investigat Surg. 20:339–348. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jacobi C, Peter FJ, Wenger FA, Ordemann J
and Müller JM: New therapeutic strategies to avoid intra- and
extraperitoneal metastases during laparoscopy: results of a tumor
model in the rat. Dig Surg. 16:393–399. 1999. View Article : Google Scholar
|
|
35
|
Jacobi C, Sabat R, Ordemann J, Wenger F,
Volk H and Müller J: Peritoneal instillation of taurolidine and
heparin for preventing intraperitoneal tumor growth and trocar
metastases in laparoscopic operations in the rat model. Langenbecks
Arch Chir. 382:S31–S36. 1997. View Article : Google Scholar
|
|
36
|
Jacobi CA, Ordemann J, Böhm B, Zieren HU,
Sabat R and Müller JM: Inhibition of peritoneal tumor cell growth
and implantation in laparoscopic surgery in a rat model. Am J
Surgery. 174:359–363. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Braumann C, Jacobi CA, Rogalla S,
Menenakos C, Fuehrer K, Trefzer U and Hofmann M: The tumor
suppressive reagent Taurolidine inhibits growth of malignant
melanoma - a mouse model. J Surg Res. 143:372–378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun BS, Wang JH, Liu LL, Gong SL and
Redmond HP: Taurolidine induces apoptosis of murine melanoma cells
in vitro and in vivo by modulation of the Bcl-2 family proteins. J
Surg Oncol. 96:241–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Walters DK, Muff R, Langsam B, Gruberer P,
Born W and Fuchs B: Taurolidine: a novel anti-neoplastic agent
induces apoptosis of osterosarcoma cell lines. Invest New Drugs.
25:305–312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marley K, Helfand SC, Edris WA, Mata JE,
Gitelman AI, Medlock J and Séguin B: The effects of taurolidine
alone and in combination with doxorubicin or carboplatin in canine
osteosarcoma in vitro. BMC Veterinary Res. 9:15–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chromik AM, Daigeler A, Bulut D, Flier A,
May C, Havati K, Roschinsky J, Sülberg D, Ritter PR, Mittelkötter
U, Hahn SA and Uhl W: Comparative analysis of cell death induction
by Taurolidine in different malignant human cancer cell lines. J
Exp Clin Cancer Res. 29:21–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Daigeler A, Chromik AM, Geisler A, Bulut
D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W and
Mittelkötter U: Synergistic apoptotic effects of taurolidine and
TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol.
32:1205–1220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Daigeler A, Chromik AM, Haendschke K,
Emmelmann S, Siepmann M, Hensel K, Schmitz G, Klein-Hitpass L,
Steinau HU, Lehnhardt M and Hauser J: Synergistic effects of
sonoporation and taurolidin/TRAIL on apoptosis in human
fibrosarcoma. Ultrasound Med Biol. 36:1893–1906. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jacobi CA, Menenakos C and Braumann C:
Taurolidine - a new drug with anti-tumor and anti-angiogenic
effects. Anticancer Drugs. 16:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Volz J, Volz-Köster S, Kanis S, Klee D,
Ahlert C and Melchert F: Modulation of tumor-induced lethality
after pneumoperitoneum in a mouse model. Cancer. 89:262–266. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Da Costa ML, Redmond HP and Bouchier-Hayes
DJ: Taurolidine improves survival by abrogating the accelerated
development and proliferation of solid tumors and development of
organ metastases from circulating tumor cells released following
surgery. J Surg Res. 101:111–119. 2001.
|
|
47
|
Chromik AM, Daigeler A, Bulut D, Flier A,
May C, Harti K, Roschinsky J, Sülberg D, Ritter PR, Mittelkötter U,
Hahn SA and Uhl W: Comparative analysis of cell death induction by
Taurolidine in different malignant human cancer cell lines. J Exp
Clin Res. 29:21–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen L, Li Y, Yu TS, McKay RM, Burns DK,
Kernie SG and Parada LF: A restricted cell population propagates
glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Trachootham D, Zhou Y, Zhang H, Demizu Y,
Chen Z, Pelicano H, Chiao PJ, Acxhanta G, Arlinghaus RB, Liu J and
Hunag P: Selective killing of oncogenically trandformed cells
through a ROS mediated mechanism by beta-phenylethyl
isothiocyanate. Cancer Cell. 10:241–252. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang P, Feng L, Oldham EA, Keating MJ and
Plunkett W: Superoxide dismutase as a target for killing of cancer
cells. Nature. 407:390–395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shaw AT, Winslow MM, Magendantz M, Ouyang
C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N and
Jacks T: Selective killing of K-ras mutant cancer cells by small
molecule inducers of oxidative stress. Proc Natl Acad Sci USA.
108:8773–8778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dolam S, Lessnick SL, Hahn WC and
Stockwell BR: Idebtificaton of genotype-selective antitumor agents
using syntheticchemical screening in engineered human tumor cells.
Cancer Cell. 3:285–296. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guzman ML, Rossi RM, Neelakantan S, Li X,
Corbett CA, Hassane DC, Becker MW, Bennet JM, et al: An orally
bioavailable parthenolide analog selectively eradicates acute
myelogenous leukemia stem and progenitor cells. Blood.
110:4427–4435. 2007. View Article : Google Scholar
|
|
54
|
O’Brien G, Cahill R, Bouchier-Hayes D and
Redmond P: Co-immunotherapy with interleukin-2 and taurolidine for
progressive metastatic melanoma. Irish J Med Sci. 175:10–14.
2006.PubMed/NCBI
|
|
55
|
Doddakula KK, Neary PM, Wang JH, Sookhai
S, O’Donnel A, et al: The antioxidant agent taurolidine potentially
reduces ischemia/reperfusion injury through its metabolite taurine.
Surgery. 148:567–572. 2010. View Article : Google Scholar
|
|
56
|
Braumann C, Guenther N, Pohlenz J,
Pfirrmann RW and Menenakos C: Wound healing is not impaired in rats
undergoing perioperative treatment with the antineoplastic agent
taurolidine. Eur Surg Res. 42:91–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Neary PM, Hallihan P, Wang JH, Pfirrmann
R, Bouchier-Haves HP and Redmond HP: The evolving role of
Taurolidine in cancer therapy. Ann Surg Oncol. 17:1135–1143. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liberko M, Kolostova K and Bobek V:
Essentials of circulating tumor cells for clinical research and
practice. Cirtic Rev Hematol Oncol. 88:338–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kilian M, Gregor JI, Heukamp I, Braumann
C, Guski H, Schimke I, Walz MK, Jacobi CA and Wenger FA: Impact of
taurolidine and octreotide on liver metastasis and lipid
peroxidation after laparoscopy in chemical induced ductal
pancreatic cancer. Invest New Drugs. 23:157–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gong L, Greenberg HE, Perhach JL, Waldman
SA and Kraft WK: The pharmacokinetics of Taurolidine metabolites in
healthy volunteers. J Clin Pharmacol. 47:697–703. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stendel R, Scheurer L, Schlatterer K,
Stalder U, Pfirrmann R, Fiss I, Möhler H and Bigler L:
Pharmacokinetics of Taurolidine follwing repeated intravenous
infusions measured by HPLC-ESI-MS/MS of the derivatives Taurultame
and taurinamide in glioblastoma patients. Clin Pharmacokinetics.
46:513–524. 2007. View Article : Google Scholar
|
|
62
|
Chromik AM, Hahn SA, Daigeler A, Flier A,
Bulut D, May C, Harati K, Roschinsky J, Sülberg D, Weyhe D,
Mittelkötter U and Uhl W: Gene expression analysis of cell death
induction by taurolidine in different malignant cell lines. BMC
Cancer. 10:595–608. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Daigeler A, Brenzel Ch, Bulut D, Geisler
A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinsträsser L,
Klein-Hitpass L, Mittelkötter U, Uhl W and Chromik AM: TRAIL and
Taurolidine induce apoptosis and decrease proliferation in human
fibrosarcoma. J Exp Clin Cancer Res. 27:82–102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Rubinsztein DC, Codogno P and Levine B:
Autophagy modulation as a potential therapeutic target for divers
diseases. Nature Rev Drug Disc. 11:709–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Möhler T, Willhauck-Fleckenstein M,
Schwartz-Albiez R, Merling A and Möhler H: Inhibition of
endothelial cell adhesion and in vitro angiogenesis by Taurolidine.
Cancer Ther. 6:623–628. 2008.
|
|
66
|
Egan BM, Bouchier-Hayes DJ, Condron C,
Kelly CJ and Abdih H: Taurolidine attenuates the hemodynamic and
respiratory changes associated with endotoxemia. Scock. 17:308–311.
2002.PubMed/NCBI
|
|
67
|
Bedrosian I, Sofia RD, Wolff SM and
Dinarello CA: Taurolidine, an analogue of the amino acid taurine,
suppresses interleukin 1 and tumor necrosis factor synthesis in
human peripheral blood mononuclear cells. Cytokine. 3:568–575.
1991. View Article : Google Scholar
|
|
68
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar
|
|
69
|
Reddy PS, Jamil K, Madhusudhan P and
Anjani G: Antibacterial activity of isolates of from Piper
longum and Taxus baccata. Pharm Biol. 39:236–238. 2001.
View Article : Google Scholar
|
|
70
|
Adams DJ, Dai M, Pellegrino G, Wagner BK,
et al: Synthesis, cellular evaluation and mechanism of action of
piperlongumine anlogs. Proc Natl Acad Sci USA. 109:15115–15120.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang Y, Wang JW, Xiao X, Shan Y, Xue B,
Jiang G, He Q, Chen J, Xu HG, Zhao RX, Werle KD, Cui R, Liang J, Li
YL and Xu ZX: Piperlongumine induces autophagy by targeting p38.
Cell Death Dis. 4:e8242013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ginzburg S, Golovine KV, Makhov PB, Uzzo
RG, Kutikov A and Kolenko VM: Piperlongumine inhibits NFkappaB
activity and attenuates aggressive growth characteristics of
prostate cancer cells. Prostate. 73:1–10. 2013.PubMed/NCBI
|
